New data has emerged regarding Boehringer Ingelheim’s obesity drug, indicating a potential limitation in its effectiveness.
The drug appears to show promise in reducing liver fat, a positive aspect for certain health outcomes.
However, the results concerning overall weight loss are reportedly less impressive, raising questions about its competitiveness in the obesity treatment market.